RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Completed · Phase 2 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infections
In brief
A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS). 86 subjects from 2 treatment groups (43 per treatment group) are supposed to receive one (booster) dose of MVA-BN-RSV vaccine approximately one year after their first vaccination. In this booster substudy, eligible subjects will receive the same dose they received during the main trial.
Key facts
- Study ID
- NCT02873286
- Run by
- Bavarian Nordic
- People needed
- 420
- Starts
- 2016-09-01
- Expected to finish
- 2018-12-01
- Last updated by the study team
- 2020-09-22
Who can join
Age: 55 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Paradigm Research — Redding, California, United States
- Optimal Research — San Diego, California, United States
- Compass Research — The Villages, Florida, United States
- Meridian Clinical Research — Savannah, Georgia, United States
- Clinical Research Atlanta — Stockbridge, Georgia, United States
- Optimal Research — Peoria, Illinois, United States
- Optimal Research — Rockville, Maryland, United States
- Washington University in St. Louis, School of Medicine — St Louis, Missouri, United States
- United Medical Associates — Binghamton, New York, United States
- Regional Clinical Research Associates — Endwell, New York, United States
- Rapid Medical Research — Cleveland, Ohio, United States
- Ventavia Research Group — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.